GO
Loading...

Pharmaceuticals

More

  • Johnson & Johnson Puts Red Cross In Legal "Cross Hairs" Thursday, 9 Aug 2007 | 12:11 PM ET
    Johnson & Johnson

    Johnson & Johnson, the drug/medical device/consumer health products company reeling from a plunge in sales of its anemia drug, Procrit, and its drug-coated stent, Cypher, is going to court. Not to defend a lucrative pharmaceutical patent, but to get The Red Cross to stop using its red cross logo on certain marketed products like humidifiers and grooming tools.

  • Johnson & Johnson Sues Red Cross Over Use of Emblem Thursday, 9 Aug 2007 | 10:27 AM ET

    Johnson & Johnson, the pharmaceutical giant which uses a Red Cross as its trademark, filed a lawsuit Wednesday against the American Red Cross, demanding that the charity halt the use of the red cross symbol on products it sells to the public.

  • Cardinal Health Reports Quarterly Net Profit Rise Thursday, 9 Aug 2007 | 7:37 AM ET

    Cardinal Health on Thursday said its quarterly net profit rose, led by strong demand for medical pumps and other devices in its Clinical Technologies and Services business.

  • Barr Pharmaceuticals Profit Down, but Beats Street Wednesday, 8 Aug 2007 | 12:27 PM ET

    Barr Pharmaceuticals said Wednesday quarterly earnings fell sharply, hurt by costs tied to an acquisition, but its operating profit beat Wall Street estimates as generic drug sales soared

  • A rebound in the financial sector and positive earnings surprises triggered gains for some of the most actively traded stocks on Tuesday.

  • GSK's Avandia: Analyzing The Analyzer (Dr. Nissen) Tuesday, 7 Aug 2007 | 10:35 AM ET

    Yep, you probably could have called this one, but researchers have done an analysis of Dr. Steven Nissen's controversial meta-analysis that started the Avandia safety scare. Their findings are published in the Annals of Internal Medicine and touted and brought to my attention in an email from a GlaxoSmithKline PR person. A meta-analysis is what one of our contacts called "a mish-mash" of a bunch of clinical trials.

  • Hot Stocks: Brokerages, Fannie Mae Among Big Movers Monday, 6 Aug 2007 | 4:24 PM ET

    Corporate news and analyst upgrades were some of the catalysts behind the most actively traded stocks on Monday.

  • Merck: As Stock Gets Upgrade Is Vioxx Coming Back? Monday, 6 Aug 2007 | 11:26 AM ET

    In very early trading MRK shares are rallying this morning on the wings of an upgrade at Cowen & Co. by analyst Steve Scala from Neutral to Outperform. He's been at a Neutral since a year and one month ago when the stock was sitting in the 30s. Today it's in the low 50s.

  • Trexima Study Update: No Hamsters Harmed Friday, 3 Aug 2007 | 2:44 PM ET
    Chinese Hamsters

    I have a clarification to make regarding my previous blog entry about the Chinese Hamster problem facing GlaxoSmithKline and Pozen. Thanks to blog-reader Brian Orelli with www.babybiotechs.com who caught the error and pointed it out in an email: "Chinese Hamster Ovary (CHO) cells are grown in tissue culture and the mega dose of the drug was given to the CHO cells growing in media in a tissue culture dish/flask in an incubator...

  • Pharmaceutical company Novo Nordisk, the world's largest producer of insulin, said Friday that second-quarter net profit more than doubled and raised its guidance for the full year. Its shares rose more than 4%.

  • Pozen and Glaxo's "Hamster Problem" With Trexima Thursday, 2 Aug 2007 | 1:57 PM ET
    Chinese Hamster

    So, I just got off the Pozen conference call about the Trexima delay (by the way, it won't be called Trexima if/when it comes to market, as the FDA is asking Glaxo for a name change. The agency sometimes does this if, for example, it believes the name looks or sounds too much like an existing drug and could confuse pharmacists.)

  • FDA Delays Approval of Glaxo, Pozen Migraine Drug Thursday, 2 Aug 2007 | 1:19 PM ET

    U.S. regulators have delayed approval of an experimental two-in-one migraine drug from GlaxoSmithKline and Pozen yet again, sending Pozen stock down 45 percent on Thursday.

  • This morning we learned that the FDA has issued another "approvable" letter to Pozen and GlaxoSmithKline for their migraine drug Trexima over safety concerns. POZN shares are down big. The company has scheduled a conference call for 11 a.m. ET. This is the third regulatory stumbling block for this drug and puts it on a timeline now where it could end up competing...

  • Big Pharma's New Business Model? Wednesday, 1 Aug 2007 | 3:27 PM ET
    Sanofi Aventis

    As several of the major pharmaceutical companies struggle through a period of a relative dearth of big, new products, the job casualties and the share buybacks are piling up this earnings season. Today, Sanofi-Aventis is joining the group. The French drugmaker announced it will buy back more than $4 billion of its stock and get rid of even more sales reps.

  • Sanofi Profits Fall Short As Generic Drugs Hit Wednesday, 1 Aug 2007 | 2:33 AM ET

    French pharmaceuticals group Sanofi-Aventis said on Wednesday second-quarter adjusted net profit fell 6.3 percent, more than analysts had expected, as generic competition and a strong euro hit sales.

  • GlaxoSmithKline: A Good Week For Avandia And Trexima? Tuesday, 31 Jul 2007 | 3:00 PM ET
    Glaxo Smith Kline

    So, GlaxoSmithKline escapes Gaithersburg with a 20-3 vote that Avandia may increase the risk of heaving a heart attack, but a 22-1 vote that the diabetes drug should stay on the market. And maybe, or maybe not, with a so-called "Black Box" warning. That'll be up to the FDA.

  • Earnings reports and corporate announcements were some of the catalysts behind the most actively traded stocks on Tuesday.

  • Digging Deep for Deals Tuesday, 31 Jul 2007 | 11:25 AM ET

    A sell-off is the perfect time to find broken stocks, and Cramer has his eye on several that investors should know about.Investing can be confusing. Luckily, Cramer has mapped out some road rules for all you Home Gamers trying to navigate the jungle that is Wall Street. Think of it as "Mad Money 101" –- some fundamental advice to keep in mind as you play the market. Whether you're a first time investor or a seasoned financier, it's always good to remember the basics.

  • Riding The Rally Tuesday, 31 Jul 2007 | 11:06 AM ET

    With stocks in rally mode, it's appropriate to drill down for answers as well as take a look at some key sectors.

  • An independent advisory panel told the U.S. Food and Drug Administration that GlaxoSmithKline's widely used diabetes pill Avandia increased heart risk but the drug should remain on the market.